Have you cited DMAB8261 in a publication? Let us know and earn a reward for your research.
Background
Cefazolin is a widely used antibiotic belonging to the cephalosporin class. It exhibits potent bactericidal activity against a broad range of bacteria, making it effective in combating both gram-positive and certain gram-negative pathogens. As a first-generation cephalosporin, cefazolin's mechanism of action involves inhibiting bacterial cell wall synthesis. It achieves this by binding to penicillin-binding proteins (PBPs), which are enzymes crucial for cross-linking the peptidoglycan strands in the bacterial cell wall. By interfering with this process, cefazolin weakens and disrupts the integrity of the bacterial cell wall, leading to cell lysis and subsequent bacterial death.
Cefazolin has demonstrated efficacy against numerous bacterial infections, including skin and soft tissue infections, surgical site infections, respiratory tract infections, urinary tract infections, and some cases of meningitis. It is frequently used as a prophylactic antibiotic to prevent surgical site infections and has a long history of safe and effective use. While generally considered safe, common adverse effects may include gastrointestinal symptoms, injection site reactions, and, rarely, allergic reactions. It is important to discuss any known allergies or previous adverse reactions to antibiotics with healthcare providers before initiating cefazolin therapy.
My Review for Anti-Cefazolin monoclonal antibody, clone DI1090
Creative Diagnostics products are for RESEARCH USE ONLY, please make sure your review is research based.
Required fields are marked with *
Terms and conditions:
We will select high-quality review customers and offer a $30 coupon for your next purchase.
All product reviews must be submitted in the English language.
Creative Diagnostics will not share any personal information of applicants, and all information will be treated with strict confidentiality and will not be sold or disclosed to a third party.
References
Evaluation of cefazolin, a new cephalosporin antibiotic
Antimicrobial Agents and Chemotherapy
Authors: Reller, L. B., Karney, W. W., Beaty, H. N., Holmes, K. K., Turck, M.
Cefazolin sodium was tested in vitro against 308 isolates of Enterobacteriaceae, Pseudomonas aeruginosa, Neisseria meningitidis, Haemophilus influenzae, Staphylococcus aureus, and enterococcus. Broth and agar dilution and disk diffusion techniques were used with at least two sizes of inocula of organisms. Cefazolin was also studied in the treatment of 85 hospitalized patients with a variety of serious infections. In concentations of 5 μg or less/ml, cefazolin inhibited and killed more than 90% of isolates of Enterobacteriaceae with the exception of indole-positive Proteus and Enterobacter species. No isolate of P. aeruginosa and only a few of Enterobacter and enterococci were killed by 25 μg of cefazolin/ml, a concentration readily attainable in serum with a 500-mg dose given intramuscularly. Penicillin-susceptible as well as penicillin-resistant isolates of S. aureus were killed by 1 μg or less of cefazolin per ml; however, 25 μg/ml was required to kill 100% of the strains when the inoculum size was increased 100-fold. Cefazolin treatment appeared effective in 82 of 85 patients, including four with endocarditis. Pain was minimal after intramuscular injection, and thrombophlebitis was not observed in those treated intravenously. No patient developed a positive Coombs test, and no evidence of renal toxicity was apparent in clinical studies.
Bactericidal activity and pharmacology of cefazolin
Antimicrobial Agents and Chemotherapy
Authors: Bergeron, M. G., Brusch, J. L., Barza, M., Weinstein, L.
The in vitro bactericidal activity of cefazolin was found to be similar to that of cephaloridine and cephalothin but slightly greater than that of cephalexin against a majority of 233 strains of gram-positive and gram-negative organisms. Cefazolin, however, was two- to eightfold more active than the other two drugs against Escherichia coli and klebsiella. The mean peak concentrations in the serum in 10 normal subjects 1 h after intramuscular injections of 1,000, 500, and 250 mg of cefazolin were 38.8, 18.6, and 12.2 μg/ml, respectively. The antibiotic could still be detected at 8 h. Peak values for a given dose of cephaloridine were comparable. However, blood levels of cefazolin were regularly higher than those of cephaloridine over the first 8 h. The mean half-life of cefazolin in the serum was 2 h, whereas that of cephaloridine was 1.4 h. The degree of serum protein-binding was strikingly higher for cefazolin (81%) than for cephaloridine (24%), suggesting that the antibacterial activity of the former in serum might be less than that of cephaloridine after equal doses. This proved to be the case when the bacterial activity of blood drawn 1, 4, and 8 h after injection of the two drugs was examined.
COA
Publication 
Loading ......
